Volume 26, Number 8—August 2020
Research Letter
Pulmonary Embolism and Increased Levels of D-Dimer in Patients with Coronavirus Disease
Table
Characteristic | Case-patient |
||
---|---|---|---|
1 | 2 | 3 | |
Age, y |
52 |
60 |
68 |
Risk factors |
Allergic rhinitis, asthma |
Chronic bronchitis, history of ovarian cancer, and history of provoked DVT |
Hypertension, diabetes mellitus type 2 |
Smoking status | Former | Never | Never |
BMI, kg/m2 | 27.0 | 27.4 | 23.7 |
Creatinine clearance, mL/min |
116 |
127.4 |
64 |
Day of symptoms, baseline/CTA | 12/18 | 8/18 | 14/22 |
O2 saturation, baseline/CTA | 52% on RA/98% on NRB | 92% on NC/91% on NC | 94% on NRB/93% on NRB |
2,283/9,698 | 221/2,563 | 33,318/1,554 | |
Ferritin, μg/L, baseline/CTA | 2,283/1,050 | 1,276/1,176 | 2,797/1,282 |
CRP, mg/L, baseline/CTA | 32.30/0.42 | 11.89/0.66 | 8.88/0.25 |
Procalcitonin, ng/mL, baseline/CTA | 0.19/0.05 | 0.05/0.13 | 0.23/NA |
LDH, U/L, baseline/CTA | 567/467 | 448/637 | 824/616 |
Neutrophil:lymphocyte ratio, baseline/CTA |
10.58/11.75 |
6.6/7.5 |
7.67/14.99 |
ISTH score, day of CTA | >5 | >5 | >5 |
VTE prevention | Enoxaparin, 40 mg 2×/d | Enoxaparin, 40 mg 2×/d | Enoxaparin, 40 mg/d |
IMPROV score | 0 | 3 | 1 |
Doses of tocilizumab | 1 | 1 | 1 |
Methylprednisolone duration, d | 8 | 5 | 5 |
Hydroxychloroquine duration, d |
5 |
5 |
5 |
CTA read | Bilateral PE; filling defects most pronounced in the right lobar pulmonary artery extending to the first-order branches of the right lower lobe pulmonary artery; additional small filling defect identified within the right upper lobe, right middle lobe, and lingular pulmonary artery branches; diffuse scattered bilateral ground-glass opacities with areas of consolidation compatible with reported viral pneumonia COVID-19 | Multiple bilateral segmental and subsegmental PE with suggestion of cardiac strain; bilateral scattered, predominantly peripheral ground-glass opacities with some interlobular septal thickening consistent with given history of COVID-19 pneumonia | Central filling defects compatible with acute pulmonary embolism in several segmental and subsegmental pulmonary arteries in the right upper lobe, right lower lobe, and left lower lobe; diffuse bilateral ground-glass opacities unchanged from previous imaging |
*BMI, body mass index; COVID-19, coronavirus disease; CRP, C-reactive protein; CTA, computed tomography angiogram; DVT, deep vein thrombosis; IMPROV, International Medical Prevention on Venous Thrombosis; ISTH, International Society of Thrombosis and Haemostasis; LDH, lactate dehydrogenase; NA, not available; NC, nasal cannula; NRB, nonrebreather; PE, pulmonary embolus; RA, room air; RLL, right lower lobe; VTE, venous thromboembolism.
Page created: April 30, 2020
Page updated: July 18, 2020
Page reviewed: July 18, 2020
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.